Huntington disease

Nature Reviews Disease Primers

Volumn 1, Issue , 2015, Pages

  Bates, Gillian P ^a   Dorsey, Ray ^b   Gusella, James F ^c   Hayden, Michael R ^d   Kay, Chris ^d   Leavitt, Blair R ^d   Nance, Martha ^e,f   Ross, Christopher A ^g   Scahill, Rachael I ^h   Wetzel, Ronald ⁱ   Wild, Edward J ^h   Tabrizi, Sarah J ^h  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Struthers Parkinson's Center   (United States)

^f HENNEPIN COUNTY MEDICAL CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BIOLOGICAL MARKER; BN 82451B; CREATINE; DEUTETRABENAZINE; EPIGALLOCATECHIN GALLATE; HUNTINGTIN; LAQUINIMOD; MERCAPTAMINE; NEUROLEPTIC AGENT; OMS 643762; PBT 2; PF 0254920; PRIDOPIDINE; TETRABENAZINE; UBIDECARENONE; UNCLASSIFIED DRUG; HTT PROTEIN, HUMAN; NERVE PROTEIN; PEPTIDE; POLYGLUTAMINE;

BRAIN ELECTROPHYSIOLOGY; COGNITIVE DEFECT; FAMILY HISTORY; GENETIC SCREENING; GENETICS; HUMAN; HUNTINGTON CHOREA; MAJOR DEPRESSION; MOTOR DYSFUNCTION; NONHUMAN; PATHOGENESIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADULT; PHENOTYPE; PREVALENCE; TRINUCLEOTIDE REPEAT;

ADULT; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; PEPTIDES; PHENOTYPE; PREVALENCE; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 85017268070     PISSN: None     EISSN: 2056676X     Source Type: Journal    
DOI: 10.1038/nrdp.2015.5     Document Type: Review

References (259)

1. Huntington, G. On chorea. Med. Surg. Rep. 26, 320-321 (1872).
2. Fisher, E. R. & Hayden, M. R. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Mov. Disord. 29, 105-114 (2014).
3. Morrison, P. J., Harding-Lester, S. & Bradley, A. Uptake of Huntington disease predictive testing in a complete population. Clin. Genet. 80, 281-286 (2011).
4. Evans, S. J. W. et al. Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J. Neurol. Neurosurg. Psychiatry 84, 1156-1160 (2013).
5. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72, 971-983 (1993).
6. Ross, C. A. et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10, 204-216 (2014).
7. Kay, C., Fisher, E. R. & Hayden, M. R. in Huntington's Disease 4th edn Ch.7 (eds Bates, G. P., Tabrizi, S. J. & Jones, L.) (Oxford Univ. Press, 2014).
8. Morrison, P. J. Prevalence estimates of Huntington disease in Caucasian populations are gross underestimates. Mov. Disord. 27, 1707-1709 (2012).
9. Almqvist, E. W., Elterman, D. S., MacLeod, P. M. & Hayden, M. R. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin. Genet. 60, 198-205 (2001).
10. Ramos-Arroyo, M. A., Moreno, S. & Valiente, A. Incidence and mutation rates of Huntington's disease in Spain: experience of 9 years of direct genetic testing. J. Neurol. Neurosurg. Psychiatry 76, 337-342 (2005).
11. Koutsis, G., Karadima, G., Kladi, A. & Panas, M. Late-onset Huntington's disease: diagnostic and prognostic considerations. Parkinsonism Relat. Disord. 20, 726-730 (2014).
12. Pringsheim, T. et al. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov. Disord. 27, 1083-1091 (2012).
13. Hayden, M. R., MacGregor, J. M. & Beighton, P. H. The prevalence of Huntington's chorea in South Africa. South Afr. Med. J. 58, 193-196 (1980).
14. Wexler, N. S. et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc. Natl Acad. Sci. USA 101, 3498-3503 (2004).
15. Squitieri, F. et al. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum. Mol. Genet. 3, 2103-2114 (1994).
16. Warby, S. C. et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am. J. Hum. Genet. 84, 351-366 (2009).
17. Costa, M. C. et al. The CAG repeat at the Huntington disease gene in the Portuguese population: insights into its dynamics and to the origin of the mutation. J. Hum. Genet. 51, 189-195 (2006).
18. Semaka, A. et al. CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. J. Med. Genet. 50, 696-703 (2013).
19. Semaka, A. et al. High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 162, 864-871 (2013).
20. Warby, S. C. et al. HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia. Eur. J. Hum. Genet. 19, 561-566 (2011).
21. Baine, F. K. et al. Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. Eur. J. Hum. Genet. 21, 1120-1127 (2013).
22. Wheeler, V. C. et al. Factors associated with HD CAG repeat instability in Huntington disease. J. Med. Genet. 44, 695-701 (2007).
23. Gusella, J. F. & Macdonald, M. Genetic criteria for Huntington's disease pathogenesis. Brain Res. Bull. 72, 78-82 (2007).
24. Gusella, J. F., MacDonald, M. E. & Lee, J. M. Genetic modifiers of Huntington's disease. Mov. Disord. 29, 1359-1365 (2014).
25. Andrew, S. E. et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 4, 398-403 (1993).
26. Duyao, M. et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4, 387-392 (1993).
27. Lee, J. M. et al. CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology 78, 690-695 (2012).
28. Snell, R. G. et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4, 393-397 (1993).
29. Rosenblatt, A. et al. Age, CAG repeat length, and clinical progression in Huntington disease. Mov. Disord. 27, 272-276 (2012).
30. Aylward, E. et al. Association between age and striatal volume stratified by CAG repeat length in prodromal Huntington disease. PLoS Curr. 3, RRN1235 (2011).
31. Seong, I. S. et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14, 2871-2880 (2005).
32. Reis, S. A. et al. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis. Hum. Mol. Genet. 20, 2344-2355 (2011).
33. HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 11, 264-278 (2012).
34. Paulsen, J. S. et al. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J. Neurol. Neurosurg. Psychiatry 79, 874-880 (2008).
35. Zuccato, C. & Cattaneo, E. in Huntington's Disease (eds Bates, G. P., Tabrizi, S. J. & Jones, L.) 243-273 (Oxford Univ. Press, 2014).
36. Andrade, M. A. & Bork, P. HEAT repeats in the Huntington's disease protein [letter]. Nat. Genet. 11, 115-116 (1995).
37. Wetzel, R. & Mishra, R. in Huntington's Disease (eds Bates, G. P., Tabrizi, S. J. & Jones, L.) 274-322 (Oxford Univ. Press, 2014).
38. Aiken, C. T. et al. Phosphorylation of threonine 3: implications for huntingtin aggregation and neurotoxicity. J. Biol. Chem. 284, 29427-29436 (2009).
39. Atwal, R. S. et al. Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity. Hum. Mol. Genet. 16, 2600-2615 (2007).
40. Tam, S. et al. The chaperonin TRiC blocks a huntingtin sequence element that promotes the conformational switch to aggregation. Nat. Struct. Mol. Biol. 16, 1279-1285 (2009).
41. Cornett, J. et al. Polyglutamine expansion of huntingtin impairs its nuclear export. Nat. Genet. 37, 198-204 (2005).
42. Rockabrand, E. et al. The first 17 amino acids of huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 16, 61-77 (2007).
43. Steffan, J. S. et al. SUMO modification of huntingtin and Huntington's disease pathology. Science 304, 100-104 (2004).
44. Jayaraman, M. et al. Slow amyloid nucleation via α-helix-rich oligomeric intermediates in short polyglutamine-containing huntingtin fragments. J. Mol. Biol. 415, 881-999 (2012).
45. Thakur, A. K. et al. Polyglutamine disruption of the huntingtin exon 1 N terminus triggers a complex aggregation mechanism. Nat. Struct. Mol. Biol. 16, 380-389 (2009).
46. Michalek, M., Salnikov, E. S., Werten, S. & Bechinger, B. Membrane interactions of the amphipathic amino terminus of huntingtin. Biochemistry 52, 847-858 (2013).
47. Wetzel, R. Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J. Mol. Biol. 421, 466-490 (2012).
48. Faber, P. W. et al. Huntingtin interacts with a family of WW domain proteins. Hum. Mol. Genet. 7, 1463-1474 (1998).
49. Caron, N. S., Desmond, C. R., Xia, J. & Truant, R. Polyglutamine domain flexibility mediates the proximity between flanking sequences in huntingtin. Proc. Natl Acad. Sci. USA 110, 14610-14615 (2013).
50. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810 (2004).
51. Davies, S. W. et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548 (1997).
52. Difiglia, M. et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993 (1997).
53. Sahl, S. J., Weiss, L. E., Duim, W. C., Frydman, J. & Moerner, W. E. Cellular inclusion bodies of mutant huntingtin exon 1 obscure small fibrillar aggregate species. Sci. Rep. 2, 895 (2012).
54. Poirier, M. A. et al. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J. Biol. Chem. 277, 41032-41037 (2002).
55. Landles, C. et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J. Biol. Chem. 285, 8808-8823 (2010).
56. Marcellin, D. et al. Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging. PLoS ONE 7, e44457 (2012).
57. Scherzinger, E. et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington disease pathology. Proc. Natl Acad. Sci. USA 96, 4604-4609 (1999).
58. Chen, S., Berthelier, V., Yang, W. & Wetzel, R. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. J. Mol. Biol. 311, 173-182 (2001).
59. Morley, J. F., Brignull, H. R., Weyers, J. J. & Morimoto, R. I. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl Acad. Sci. USA 99, 10417-10422 (2002).
60. Ossato, G. et al. A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis. Biophys. J. 98, 3078-3085 (2010).
61. Chen, S., Ferrone, F. A. & Wetzel, R. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation. Proc. Natl Acad. Sci. USA 99, 11884-11889 (2002).
62. Lunkes, A. et al. Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol. Cell 10, 259-269 (2002).
63. Landwehrmeyer, G. B. et al. Huntington's disease gene: regional and cellular expression in brain of normal and affected individuals. Ann. Neurol. 37, 218-230 (1995).
64. Sathasivam, K. et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc. Natl Acad. Sci. USA 110, 2366-2370 (2013).
65. Hughes, A. & Jones, L. in Huntington's Disease (eds Bates, G. P., Tabrizi, S. J. & Jones, L.) 323-369 (Oxford Univ. Press, 2014).
66. Trottier, Y. et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 378, 403-406 (1995).
67. Klein, F. A. C. et al. Linear and extended: a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10. Hum. Mol. Genet. 22, 4215-4223 (2013).
68. Levine, M. S., Wang, E. A., Chen, J. Y., Cepeda, C. & Andre, V. M. in Huntington's Disease (eds Bates, G. P., Tabrizi, S. J. & Jones, L.) 218-242 (Oxford Univ. Press, 2014).
69. Kennedy, L. et al. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum. Mol. Genet. 12, 3359-3367 (2003).
70. Gonitel, R. et al. DNA instability in postmitotic neurons. Proc. Natl Acad. Sci. USA 105, 3467-3472 (2008).
71. Manley, K., Shirley, T. L., Flaherty, L. & Messer, A. Msh2 deficiency prevents in vivo somatic instability of the CAG repeat in Huntington disease transgenic mice. Nat. Genet. 23, 471-473 (1999).
72. Tome, S. et al. MSH3 polymorphisms and protein levels affect CAG repeat instability in Huntington's disease mice. PLoS Genet. 9, e1003280 (2013).
73. Pinto, R. M. et al. Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington's disease mice: genome-wide and candidate approaches. PLoS Genet. 9, e1003930 (2013).
74. Kovalenko, M. et al. Msh2 acts in medium-spiny striatal neurons as an enhancer of CAG instability and mutant huntingtin phenotypes in Huntington's disease knock-in mice. PLoS ONE 7, e44273 (2012).
75. Wheeler, V. C. et al. Mismatch repair gene Msh2 modifies the timing of early disease in Hdh(Q111) striatum. Hum. Mol. Genet. 12, 273-281 (2003).
76. Swami, M. et al. Somatic expansion of the Huntington's disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum. Mol. Genet. 18, 3039-3047 (2009).
77. Kim, M. et al. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J. Neurosci. 19, 964-973 (1999).
78. Moffitt, H., McPhail, G. D., Woodman, B., Hobbs, C. & Bates, G. P. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS ONE 4, e8025 (2009).
79. Frost, B. & Diamond, M. I. Prion-like mechanisms in neurodegenerative diseases. Nat. Rev. Neurosci. 11, 155-159 (2010).
80. Yang, W., Dunlap, J. R., Andrews, R. B. & Wetzel, R. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum. Mol. Genet. 11, 2905-2917 (2002).
81. Ren, P. H. et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat. Cell Biol. 11, 219-225 (2009).
82. Cicchetti, F. et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann. Neurol. 76, 31-42 (2014).
83. Pecho-Vrieseling, E. et al. Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons. Nat. Neurosci. 17, 1064-1072 (2014).
84. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D. & Housman, D. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl Acad. Sci. USA 96, 11404-11409 (1999).
85. Balch, W. E., Morimoto, R. I., Dillin, A. & Kelly, J. W. Adapting proteostasis for disease intervention. Science 319, 916-919 (2008).
86. Labbadia, J. & Morimoto, R. I. Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem. Sci. 38, 378-385 (2013).
87. Vidal, R., Caballero, B., Couve, A. & Hetz, C. Converging pathways in the occurrence of endoplasmic reticulum (ER) stress in Huntington's disease. Curr. Mol. Med. 11, 1-12 (2011).
88. Ortega, Z. & Lucas, J. J. Ubiquitin-proteasome system involvement in Huntington's disease. Front. Mol. Neurosci. 7, 77 (2014).
89. Martin, D. D. O., Ladha, S., Ehrnhoefer, D. E. & Hayden, M. R. Autophagy in Huntington disease and huntingtin in autophagy. Trends Neurosci. 38, 26-35 (2014).
90. Labbadia, J. et al. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J. Clin. Invest. 121, 3306-3319 (2011).
91. Seredenina, T. & Luthi-Carter, R. What have we learned from gene expression profiles in Huntington's disease? Neurobiol. Dis. 45, 83-98 (2012).
92. Reddy, P. H. & Shirendeb, U. P. Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease. Biochim. Biophys. Acta 1822, 101-110 (2012).
93. Johri, A., Chandra, A. & Beal, M. F. PGC-1α, mitochondrial dysfunction, and Huntington's disease. Free Radic. Biol. Med. 62, 37-46 (2013).
94. Nithianantharajah, J. & Hannan, A. J. Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease. Neuroscience 251, 66-74 (2013).
95. Ellrichmann, G., Reick, C., Saft, C. & Linker, R. A. The role of the immune system in Huntington's disease. Clin. Dev. Immunol. 2013, 541259 (2013).
96. Wang, N. et al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington disease. Nat. Med. 20, 536-541 (2014).
97. Huntington Study Group Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov. Disord. 11, 136-142 (1996).
98. Reilmann, R., Leavitt, B. R. & Ross, C. A. Diagnostic criteria for Huntington's disease based on natural history. Mov. Disord. 29, 1335-1341 (2014).
99. Cardoso, F. Differential diagnosis of Huntington disease: what the clinician should know. Neurodegener. Dis. Manag. 4, 67-72 (2014).
100. Williamson, S., Kirkpatrick, M., Greene, S. & Goudie, D. A novel mutation of NKX2-1 affecting 2 generations with hypothyroidism and choreoathetosis: part of the spectrum of brain-thyroid-lung syndrome. J. Child Neurol. 29, 666-669 (2014).
101. Hensman Moss, D. J. et al. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology 82, 292-299 (2014).
102. Craufurd, D. et al. Diagnostic genetic testing for Huntington's disease. Pract. Neurol. 15, 80-84 (2015).
103. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington's Chorea Guidelines for the molecular genetics predictive test in Huntington's disease. Neurology 44, 1533-1536 (1994).
104. MacLeod, R. et al. Experiences of predictive testing in young people at risk of Huntington's disease, familial cardiomyopathy or hereditary breast and ovarian cancer. Eur. J. Hum. Genet. 22, 396-401 (2014).
105. Hawkins, A. K., Creighton, S., Ho, A., McManus, B. & Hayden, M. R. Providing predictive testing for Huntington disease via telehealth: results of a pilot study in British Columbia, Canada. Clin. Genet. 84, 60-64 (2013).
106. De Die-Smulders, C. E. M., de Wert, G. M. W. R., Liebaers, I., Tibben, A. & Evers-Kiebooms, G. Reproductive options for prospective parents in families with Huntington's disease: clinical, psychological and ethical reflections. Hum. Reprod. Update 19, 304-315 (2013).
107. Schulman, J. D. & Stern, H. J. Low utilization of prenatal and preimplantation genetic diagnosis in Huntington disease - risk discounting in preventive genetics. Clin. Genet. http://dx.doi.org/10.1111/ cge.12523 (2014).
108. Van Rij, M. C. et al. The uptake and outcome of prenatal and pre-implantation genetic diagnosis for Huntington's disease in the Netherlands (1998-2008). Clin. Genet. 85, 87-95 (2014).
109. Semaka, A. & Hayden, M. R. Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results. Clin. Genet. 85, 303-311 (2014).
110. Langbehn, D. R., Hayden, M. R. & Paulsen, J. S. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 153B, 397-408 (2010).
111. Rosenblatt, A. et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 66, 1016-1020 (2006).
112. Tabrizi, S. J. et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol. 12, 637-649 (2013).
113. Penney, J. B., Vonsattel, J. P., MacDonald, M. E., Gusella, J. F. & Myers, R. H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 41, 689-692 (1997).
114. Warner, J. H. & Hayden, M. A new model for age-at-onset in Huntington's disease. Found. Huntington' Dis. Ther. Conference (2012).
115. Dorsey, E. R. et al. Natural history of Huntington disease. JAMA Neurol. 70, 1520-1530 (2013).
116. Paulsen, J. S. et al. Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: a decade of the PREDICT-HD study. Front. Aging Neurosci. 6, 78 (2014).
117. Rosenblatt, A. et al. Predictors of neuropathological severity in 100 patients with Huntington's disease. Ann. Neurol. 54, 488-493 (2003).
118. Hogarth, P. et al. Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov. Disord. 20, 293-297 (2005).
119. Reilmann, R. et al. Grasping premanifest Huntington's disease - shaping new endpoints for new trials. Mov. Disord. 25, 2858-2862 (2010).
120. Reilmann, R. et al. Q-motor-Quantitative motor assessments: Potential novel endpoints for clinical trials in pre-manifest and symptomatic Huntington's disease-36 months longitudinal results from the multicenter TRACK-HD study. Basal Ganglia 3, 67-68 (2013).
121. Stout, J. C. et al. Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25, 1-14 (2011).
122. Peavy, G. M. et al. Cognitive and functional decline in Huntington's disease: dementia criteria revisited. Mov. Disord. 25, 1163-1169 (2010).
123. Aretouli, E. & Brandt, J. Episodic memory in dementia: Characteristics of new learning that differentiate Alzheimer's, Huntington's, and Parkinson's diseases. Arch. Clin. Neuropsychol. 25, 396-409 (2010).
124. Folstein, S. E., Jensen, B., Leigh, R. J. & Folstein, M. F. The measurement of abnormal movement: methods developed for Huntington's disease. Neurobehav. Toxicol. Teratol. 5, 605-609 (1983).
125. Stout, J. C. et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J. Neurol. Neurosurg. Psychiatry 83, 687-694 (2012).
126. Duff, K. et al. "Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J. Neuropsychiatry Clin. Neurosci. 22, 196-207 (2010).
127. Papoutsi, M., Labuschagne, I., Tabrizi, S. J. & Stout, J. C. The cognitive burden in Huntington's disease: pathology, phenotype, and mechanisms of compensation. Mov. Disord. 29, 673-683 (2014).
128. Tabrizi, S. J. et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 10, 31-42 (2011).
129. Tabrizi, S. J. et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 11, 42-53 (2012).
130. Thompson, J. C. et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. J. Neuropsychiatry Clin. Neurosci. 24, 53-60 (2012).
131. Killoran, A. & Biglan, K. M. Current therapeutic options for Huntington's disease: Good clinical practice versus evidence-based approaches? Mov. Disord. 29, 1404-1413 (2014).
132. Van Duijn, E. et al. Neuropsychiatric symptoms in a European Huntington's disease cohort (REGISTRY). J. Neurol. Neurosurg. Psychiatry 85, 1411-1418 (2014).
133. Nance, M. A. Comprehensive care in Huntington's disease: a physician's perspective. Brain Res. Bull. 72, 175-178 (2007).
134. Simpson, S. A. & Rae, D. A standard of care for Huntington's disease: who, what and why. Neurodegener. Dis. Manag. 2, 1-5 (2012).
135. Klager, J., Duckett, A., Sandler, S. & Moskowitz, C. Huntington's disease: a caring approach to the end of life. Care Manag. J. 9, 75-81 (2008).
136. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66, 366-372 (2006).
137. Jankovic, J. & Roos, R. A. C. Chorea associated with Huntington's disease: to treat or not to treat? Mov. Disord. 29, 1414-1418 (2014).
138. Gonzalez, V. et al. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study. J. Neurosurg. 121, 114-122 (2014).
139. Study evaluating the safety, tolerability and brain function of 2 doses of PF-02545920 in subjects with early Huntington's disease [online], https://www. clinicaltrials.gov/ct2/show/NCT01806896 (2014).
140. First time use of SD-809 in Huntington disease (first-HD) [online], https://clinicaltrials.gov/ct2/show/ NCT01795859 (2013).
141. Mestre, T. A. & Ferreira, J. J. An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat. Disord. 18, 316-320 (2012).
142. Bonelli, R. M. & Hofmann, P. A systematic review of the treatment studies in Huntington's disease since 1990. Expert Opin. Pharmacother. 8, 141-153 (2007).
143. Burgunder, J.-M. et al. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. PLoS Curr. 3, RRN1260 (2011).
144. Groves, M. et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease. PLoS Curr. 3, RRN1259 (2011).
145. Anderson, K. et al. An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington's disease. PLoS Curr. 3, RRN1261 (2011).
146. Ribao, P. et al. Psychiatric and cognitive difficulties as indicators of juvenile huntington disease onset in 29 patients. Arch. Neurol. 64, 813-819 (2007).
147. Quarrell, O. W. J. et al. Managing juvenile Huntington's disease. Neurodegener. Dis. Manag. 3, 267-276 (2013).
148. Dellefield, M. E. & Ferrini, R. Promoting Excellence in End-of-Life Care: lessons learned from a cohort of nursing home residents with advanced Huntington disease. J. Neurosci. Nurs. 43, 186-192 (2011).
149. Nance, M. A. & Sanders, G. Characteristics of individuals with Huntington disease in long-term care. Mov. Disord. 11, 542-548 (1996).
150. Moskowitz, C. B. & Marder, K. Palliative care for people with late-stage Huntington's disease. Neurol. Clin. 19, 849-865 (2001).
151. Bonelli, R. M. & Wenning, G. K. Pharmacological management of Huntington's disease: an evidence-based review. Curr. Pharm. Des. 12, 2701-2720 (2006).
152. Braun, M. M., Farag-El-Massah, S., Xu, K. & Coti, T. R. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat. Rev. Drug Discov. 9, 519-522 (2010).
153. Woodcock, J. The future of orphan drug development. Clin. Pharmacol. Ther. 92, 146-148 (2012).
154. Huntington Study Group HART Investigators. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov. Disord. 28, 1407-1415 (2013).
155. De Yebenes, J. G. et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. Neurol. 10, 1049-1057 (2011).
156. Huntington Study Group Reach2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 14, 39-47 (2015).
157. Leuti, A. et al. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 52, 104-116 (2013).
158. Raptor Pharmaceuticals. Raptor announces clinical results with rp103 in Huntington's disease Phase 2/3 trial [online], http://ir.raptorpharma.com/releasedetail. cfm?releaseid=826962 (2014).
159. Coenzyme Q10 in Huntington disease. Huntingdon Study Group [online], http://www.huntington-study-group.org/CurrentHSGClinicalTrials/2CARE/tabid/95/ Default.aspx (2014).
160. Announcement of CREST-E early study group. Huntingdon Study Group [online], http://www. huntington-study-group.org/CurrentHSGClinicalTrials/ CRESTE/tabid/105/Default.aspx (2014).
161. Van der Meer, L. B., van Duijn, E., Wolterbeek, R. & Tibben, A. Adverse childhood experiences of persons at risk for Huntington's disease or BRCA1/2 hereditary breast/ovarian cancer. Clin. Genet. 81, 18-23 (2012).
162. Driessnack, M., Williams, J. K., Barnette, J. J., Sparbel, K. J. & Paulsen, J. S. Development of the HD-Teen Inventory. Clin. Nurs. Res. 21, 213-223 (2012).
163. Quaid, K. A. et al. Living at risk: concealing risk and preserving hope in Huntington disease. J. Genet. Couns. 17, 117-128 (2008).
164. Hocaoglu, M. B., Gaffan, E. A. & Ho, A. K. The Huntington's disease health-related quality of life questionnaire (HDQoL): a disease-specific measure of health-related quality of life. Clin. Genet. 81, 117-122 (2012).
165. Hocaoglu, M. B., Gaffan, E. A. & Ho, A. K. Health-related quality of life in Huntington's disease patients: a comparison of proxy assessment and patient self-rating using the disease-specific Huntington's disease health-related quality of life questionnaire (HDQoL). J. Neurol. 259, 1793-1800 (2012).
166. Clay, E. et al. Validation of the first quality-of-life measurement for patients with Huntington's disease: the Huntington Quality of Life Instrument. Int. Clin. Psychopharmacol. 27, 208-214 (2012).
167. Carlozzi, N. E. et al. HD-PRO-TRIADTM validation: a patient-reported instrument for the symptom triad of Huntington's disease. Tremor Other Hyperkinet. Mov. 4, 223 (2014).
168. Read, J. et al. Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners. J. Huntingtons. Dis. 2, 159-175 (2013).
169. Ho, A. K., Gilbert, A. S., Mason, S. L., Goodman, A. O. & Barker, R. A. Health-related quality of life in Huntington's disease: Which factors matter most? Mov. Disord. 24, 574-578 (2009).
170. Carlozzi, N. E. & Tulsky, D. S. Identification of health-related quality of life (HRQOL) issues relevant to individuals with Huntington disease. J. Health Psychol. 18, 212-225 (2013).
171. Wheelock, V. L. et al. Predictors of nursing home placement in Huntington disease. Neurology 60, 998-1001 (2003).
172. Rosenblatt, A., Kumar, B. V., Margolis, R. L., Welsh, C. S. & Ross, C. A. Factors contributing to institutionalization in patients with Huntington's disease. Mov. Disord. 26, 1711-1716 (2011).
173. Booij, S. J., Tibben, A., Engberts, D. P., Marinus, J. & Roos, R. A. C. Thinking about the end of life: a common issue for patients with Huntington's disease. J. Neurol. 261, 2184-2191 (2014).
174. Zwilling, D. et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145, 863-874 (2011).
175. Stout, J. C. et al. HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease 1,2,3. Mov. Disord. 29, 1281-1288 (2014).
176. Weir, D. W., Sturrock, A. & Leavitt, B. R. Development of biomarkers for Huntington's disease. Lancet Neurol. 10, 573-590 (2011).
177. Weiss, A. et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J. Clin. Invest. 122, 3731-3736 (2012).
178. Fang, Q. et al. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol. Cell. Proteom. 8, 451-466 (2009).
179. Wild, E., Björkqvist, M. & Tabrizi, S. J. Immune markers for Huntington's disease? Expert Rev. Neurother. 8, 1779-1781 (2008).
180. Dalrymple, A. et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J. Proteome Res. 6, 2833-2840 (2007).
181. Björkqvist, M. et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med. 205, 1869-1877 (2008).
182. Borowsky, B. et al. 8OHdG is not a biomarker for Huntington disease state or progression. Neurology 80, 1934-1941 (2013).
183. Nguyen, L., Bradshaw, J. L., Stout, J. C., Croft, R. J. & Georgiou-Karistianis, N. Electrophysiological measures as potential biomarkers in Huntington's disease: review and future directions. Brain Res. Rev. 64, 177-194 (2010).
184. Beste, C., Saft, C., Andrich, J., Gold, R. & Falkenstein, M. Stimulus-response compatibility in Huntington's disease: a cognitive-neurophysiological analysis. J. Neurophysiol. 99, 1213-1223 (2008).
185. Beste, C. et al. Alterations in voluntary movement execution in Huntington's disease are related to the dominant motor system: evidence from event-related potentials. Exp. Neurol. 216, 148-157 (2009).
186. Beniczky, S. et al. Somatosensory evoked potentials correlate with genetics in Huntington's disease. Neuroreport 13, 2295-2298 (2002).
187. Weiss, A. et al. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal. Biochem. 395, 8-15 (2009).
188. Moscovitch-Lopatin, M. et al. Optimization of an HTRF assay for the detection of soluble mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington disease. PLoS Curr. 2, RRN1205 (2010).
189. Tabrizi, S. J. et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet. Neurol. 8, 791-801 (2009).
190. Hersch, S. M. et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66, 250-252 (2006).
191. Squitieri, F. et al. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur. J. Nucl. Med. Mol. Imag. 36, 1113-1120 (2009).
192. Sturrock, A. et al. Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 75, 1702-1710 (2010).
193. Eidelberg, D. & Surmeier, D. J. Brain networks in Huntington disease. J. Clin. Invest. 121, 484-492 (2011).
194. Tang, C. C. et al. Metabolic network as a progression biomarker of premanifest Huntington's disease. J. Clin. Invest. 123, 4076-4088 (2013).
195. Esmaeilzadeh, M., Kullingsjö, J., Ullman, H., Varrone, A. & Tedroff, J. Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease. Clin. Neuropharmacol. 34, 95-100 (2011).
196. Tai, Y. F. et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 130, 1759-1766 (2007).
197. Poudel, G. R. et al. White matter connectivity reflects clinical and cognitive status in Huntington's disease. Neurobiol. Dis. 65, 180-187 (2014).
198. Bullmore, E. & Sporns, O. Complex brain networks: graph theoretical analysis of structural and functional systems. Nat. Rev. Neurosci. 10, 186-198 (2009).
199. Pavese, N. et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol. Dis. 37, 356-361 (2010).
200. Sampaio, C., Borowsky, B. & Reilmann, R. Clinical trials in Huntington's disease: interventions in early clinical development and newer methodological approaches. Mov. Disord. 29, 1419-1428 (2014).
201. Reilmann, R., Bohlen, S., Kirsten, F., Ringelstein, E. B. & Lange, H. W. Assessment of involuntary choreatic movements in Huntington's disease - toward objective and quantitative measures. Mov. Disord. 26, 2267-2273 (2011).
202. Kozauer, N. & Katz, R. Regulatory innovation and drug development for early-stage Alzheimer's disease. N. Engl. J. Med. 368, 1169-1171 (2013).
203. Rosas, H. D. et al. PRECREST: a Phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 82, 850-857 (2014).
204. Chandra, A., Johri, A. & Beal, M. F. Prospects for neuroprotective therapies in prodromal Huntington's disease. Mov. Disord. 29, 285-293 (2014).
205. Gusella, J. F. et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306, 234-238 (1983).
206. Olding-Smee, L. Biomedical philanthropy: The money tree. Nature 447, 251-251 (2007).
207. Harper, S. Q. et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl Acad. Sci. USA 102, 5820-5825 (2005).
208. Carroll, J. B. et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Mol. Ther. 19, 2178-2185 (2011).
209. Stanek, L. M. et al. Silencing mutant huntingtin by AAV-mediated RNAi ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum. Gene Ther. 25, 461-474 (2014).
210. Kordasiewicz, H. B. et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74, 1031-1044 (2012).
211. Miller, T. M. et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12, 435-442 (2013).
212. Isis Pharmaceuticals reports data from ISIS-SMN Rx Phase 2 studies in infants and children with spinal muscular atrophy. ISIS Pharmaceuticals [online], http:// ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=1976144 (2014).
213. Tabrizi, S. J. Huntingtin lowering as a treatment for Huntington's disease. European Huntington's Disease Network Plenary Meeting (2014).
214. Dragatsis, I., Levine, M. S. & Zeitlin, S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat. Genet. 26, 300-306 (2000).
215. Garriga-Canut, M. et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc. Natl Acad. Sci. 109, E3136-E3145 (2012).
216. Zeitler, S. B.et al. Allele-specific repression of mutant Huntingtin expression by engineered zinc finger transcriptional repressors as a potential therapy for Huntington's disease. Society for Neuroscience Annual Meeting [online], http://www.abstractsonline. com/Plan/ViewAbstract.aspx?sKey=036f4722-3981-4c95-a391-6d5e2d3a2433&cKey=612cd78d-04f2-42de-9d00-49f3591b9536&mKey=8d2a5bec-4825-4cd6-9439-b42bb151d1cf (2013).
217. Gu, X. et al. Serines 13 and 16 are critical determinants of full-length human mutant huntingtin induced disease pathogenesis in HD mice. Neuron 64, 828-840 (2009).
218. Atwal, R. S. et al. Kinase inhibitors modulate huntingtin cell localization and toxicity. Nat. Chem. Biol. 7, 453-460 (2011).
219. Zala, D. et al. Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum. Mol. Genet. 17, 3837-3846 (2008).
220. Di Pardo, A. et al. Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease mice. Proc. Natl Acad. Sci. 109, 3528-3533 (2012).
221. Labbadia, J. et al. Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain 135, 1180-1196 (2012).
222. Sontag, E. M. et al. Exogenous delivery of chaperonin subunit fragment ApiCCT1 modulates mutant Huntingtin cellular phenotypes. Proc. Natl Acad. Sci. USA 110, 3077-3082 (2013).
223. Ravikumar, B. et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585-595 (2004).
224. Renna, M., Jimenez-Sanchez, M., Sarkar, S. & Rubinsztein, D. C. Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J. Biol. Chem. 285, 11061-11067 (2010).
225. Smith, M. R. et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. Hum. Mol. Genet. 23, 2995-3007 (2014).
226. Reilmann, R. et al. Safety and tolerability of selisistat for the treatment of Huntington's disease: results from a randomized, double-blind, placebo-controlled Phase II trial (S47.004). Neurology 82, S47.004 (2014).
227. Mielcarek, M. et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. PLoS Biol. 11, e1001717 (2013).
228. Moumn, L., Campbell, K., Howland, D., Ouyang, Y. & Bates, G. P. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. PLoS ONE 7, e31080 (2012).
229. Bobrowska, A., Paganetti, P., Matthias, P. & Bates, G. P. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS ONE 6, e20696 (2011).
230. Benn, C. L. et al. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS ONE 4, e5747 (2009).
231. Hockly, E. et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc. Natl Acad. Sci. USA 100, 2041-2046 (2003).
232. Threlfell, S., Sammut, S., Menniti, F. S., Schmidt, C. J. & West, A. R. Inhibition of phosphodiesterase 10a increases the responsiveness of striatal projection neurons to cortical stimulation. J. Pharmacol. Exp. Ther. 328, 785-795 (2009).
233. Threlfell, S. & West, A. R. Modulation of striatal neuron activity by cyclic nucleotide signalling and phosphodiesterase inhibition. Basal Ganglia 3, 137-146 (2013).
234. Giamp, C. et al. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington disease. PLoS ONE 5, e13417 (2010).
235. Safety and efficacy of OMS643762 in subjects with Huntington's disease. [online], https://clinicaltrials.gov/ ct2/show/NCT02074410 (2014).
236. Kells, A. P. et al. AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease. Mol. Ther. 9, 682-688 (2004).
237. Pineda, J. R. et al. Neuroprotection by GDNF-secreting stem cells in a Huntington's disease model: optical neuroimage tracking of brain-grafted cells. Gene Ther. 14, 118-128 (2006).
238. Marks Jr., W. J. et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 9, 1164-1172 (2010).
239. Jiang, M. et al. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum. Mol. Genet. 22, 2462-2470 (2013).
240. Simmons, D. A. et al. A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J. Neurosci. 33, 18712-18727 (2013).
241. Todd, D. et al. A monoclonal antibody TrkB receptor agonist as a potential therapeutic for Huntington's disease. PLoS ONE 9, e87923 (2014).
242. Vecsei, L., Szalardy, L., Fulop, F. & Toldi, J. Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 12, 64-82 (2013).
243. Giorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C. & Muchowski, P. J. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat. Genet. 37, 526-531 (2005).
244. Campesan, S. et al. The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr. Biol. 21, 961-966 (2011).
245. Mrzljak, L. Development of kynurenine monooxygenase (K. M. O.) inhibitor C. H.D. I.-340246 for the treatment of Huntington's disease: a progress update. CHDI Foundation 7th Annual HD Therapeutics Conference (2013).
246. Trer, U. et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain 137, 819-833 (2014).
247. A clinical study in subjects with Huntington's disease to assess the efficacy and safety of three oral doses of laquinimod. [online], https://clinicaltrials.gov/ct2/ show/NCT02215616 (2014).
248. Gianfriddo, M., Melani, A., Turchi, D., Giovannini, M. G. & Pedata, F. Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol. Dis. 17, 77-88 (2004).
249. Liu, Y. F. Expression of polyglutamine-expanded huntingtin activates the SEK1-JNK pathway and induces apoptosis in a hippocampal neuronal cell line. J. Biol. Chem. 273, 28873-28877 (1998).
250. Apostol, B. L. et al. Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum. Mol. Genet. 15, 273-285 (2006).
251. Ferrante, R. J. et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J. Neurosci. 23, 9418-9427 (2003).
252. Taylor, D. M. et al. MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. J. Neurosci. 33, 2313-2325 (2013).
253. Apostol, B. L. et al. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice. Mol. Cell. Neurosci. 39, 8-20 (2008).
254. Mrzljak, L. & Munoz-Sanjuan, I. Therapeutic strategies for Huntington's disease. Curr. Top. Behav. Neurosci. http://dx.doi.org/10.1007/7854-2013-250 (2013).
255. Wild, E. J. & Tabrizi, S. J. Targets for future clinical trials in Huntington's disease: what's in the pipeline? Mov. Disord. 29, 1434-1445 (2014).
256. Omeros provides update on PDE10 inhibitor program. PRNewswire [online], http://www.prnewswire.com/ news-releases/omeros-provides-update-on-pde10-inhibitor-program-322137646.html (2014)
257. Hobbs, N. Z. et al. Evaluation of multi-modal, multi-site neuroimaging measures in Huntington's disease: baseline results from the PADDINGTON study. NeuroImage. Clin. 2, 204-211 (2012).
258. Constantinescu, R., Zetterberg, H., Holmberg, B. & Rosengren, L. Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders. Parkinsonism Relat. Disord. 15, 205-212 (2009).
259. Leoni, V. et al. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain 131, 2851-2859 (2008).